Cannabidiol (CBD) has gained significant attention for its potential role in pain management. Derived from Cannabis sativa L., CBD is a non-psychoactive cannabinoid that has demonstrated analgesic and anti-inflammatory properties in both preclinical and clinical studies. Because it does not produce intoxicating effects, CBD has become an attractive option for individuals seeking alternatives to traditional pain therapies.
As interest in cannabinoid-based products continues to grow across pharmaceuticals, OTC wellness, and pet health, topical CBD formulations have emerged as a promising approach for localized pain relief. Creams, gels, and balms allow CBD to be applied directly to affected areas such as joints or muscles.
However, despite its therapeutic potential, topical CBD products often face a fundamental limitation: efficient delivery through the skin.
The Challenge: CBD’s Poor Water Solubility
CBD is a highly hydrophobic (lipophilic) molecule, meaning it dissolves readily in oils but poorly in water. While this property may simplify certain oil-based formulations, it presents a major challenge for topical delivery.
Although the skin surface contains oils produced by sebaceous glands, substances that penetrate the skin must pass through both lipid and aqueous transport pathways. Water-based pathways play an important role in reaching deeper layers of the skin, particularly the dermis, where many therapeutic targets are located. Because CBD is naturally oil-based, some skin permeation can occur, but its movement through these aqueous pathways is limited. As a result, only a small fraction of conventional CBD reaches deeper tissue layers where therapeutic effects are most likely to occur, while much of the compound remains near the skin surface.
This limitation can lead to:
- Inefficient absorption
- Delayed onset of action
- Inconsistent therapeutic outcomes across formulations
Several published studies demonstrate the potential benefits of topical CBD for pain relief and improved mobility. However, outcomes can vary depending on how effectively the cannabinoid is delivered through the skin. These differences highlight a key challenge with conventional oil-based CBD formulations: limited penetration through the skin’s predominantly water-based pathways, which can result in inconsistent delivery to deeper tissues where therapeutic targets are located.
These mixed results highlight an important reality for cannabinoid formulations: the therapeutic potential of CBD depends heavily on its ability to reach target tissues.
Trait’s Solution: Water-Soluble CBD
Trait Biosciences leverages the benefits demonstrated in studies showing positive pain reduction by addressing the delivery challenges of conventional CBD. Through a proprietary glycosylation technology, Trait converts traditional water-insoluble CBD into a water-soluble, hydrophilic cannabinoid ingredient innovated to improve compatibility with the skin’s aqueous pathways and enhance tissue penetration.
Trait CBD preserves the biological activity of the original CBD while significantly improving its physicochemical properties for topical delivery.
Trait CBD is manufactured under pharmaceutical-quality standards, providing formulation partners with a reliable and scalable ingredient designed for consistent performance.
Why Hydrophilicity Matters for Skin Delivery
Successful topical therapeutics require active ingredients that can effectively cross the skin barrier and distribute into underlying tissues.
Two important properties strongly influence this process:
- Partition coefficient (Log P)
Compounds with a Log P between 1 and 5 typically show optimal skin permeability.
- Conventional CBD: Log P ≈ 6.3
- Trait CBD: within the optimal permeability range
- Water solubility Trait CBD: > 1 mg/mL
- Conventional CBD: < 0.1 mg/mL
- Trait CBD: > 1 mg/mL
These improvements enable more efficient epithelial transport and tissue distribution, both critical factors for effective topical delivery.
Faster Absorption and Improved Delivery
The improved physicochemical profile of Trait CBD translates directly into measurable performance advantages.
In epithelial transport studies comparing Trait CBD to conventional CBD, Trait CBD demonstrated approximately 10-fold higher epithelial transport within the first 40 minutes, indicating faster movement across biological barriers.
Improved absorption kinetics may support:
- Faster onset of action
- Improved bioavailability at the target site
- More consistent therapeutic outcomes across formulations
Evidence of Efficacy in Mobility and Pain Models
The enhanced delivery characteristics of Trait CBD have also been evaluated in vivo.
In a 14-day study assessing joint pain and mobility in dogs and cats:
- The proportion of animals reporting moderate or severe joint pain decreased from 91% to 18% (p < 0.001)
- The proportion reporting moderate or severe mobility challenges decreased from 65% to 17% (p < 0.01)
These results demonstrate statistically significant improvements in both pain and mobility, supporting the therapeutic potential of improved cannabinoid delivery.
Expanding Formulation Possibilities
Beyond improving performance, water-soluble cannabinoids also unlock new formulation opportunities for product developers.
Conventional CBD typically requires oil-based delivery systems. In contrast, Trait CBD enables innovative water-based topical formats, including:
- Gels
- Sprays
- Transdermal patches
- Lightweight lotions
These options allow brands to create modern topical products with improved sensory properties, formulation flexibility, and enhanced cannabinoid delivery.
A New Generation of Topical Cannabinoids
As the cannabinoid market continues to mature, delivery technology will play an increasingly important role in determining product performance and differentiation.
By improving hydrophilicity and water solubility, Trait CBD addresses one of the key limitations of conventional cannabinoids. The result is a cannabinoid ingredient designed to deliver:
- Improved skin penetration
- Faster onset of action
- More reproducible therapeutic outcomes
- Expanded formulation opportunities
For companies developing next-generation topical pain relief products, advances in cannabinoid delivery may be just as important as the cannabinoid itself.